These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

797 related articles for article (PubMed ID: 15197804)

  • 1. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
    Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
    Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
    Rosen LS; Gordon D; Tchekmedyian S; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; de Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman JJ
    J Clin Oncol; 2003 Aug; 21(16):3150-7. PubMed ID: 12915606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
    Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
    Lipton A; Zheng M; Seaman J
    Cancer; 2003 Sep; 98(5):962-9. PubMed ID: 12942563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
    Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S
    J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.
    Hirsh V; Tchekmedyian NS; Rosen LS; Zheng M; Hei YJ
    Clin Lung Cancer; 2004 Nov; 6(3):170-4. PubMed ID: 15555218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
    Lipton A; Colombo-Berra A; Bukowski RM; Rosen L; Zheng M; Urbanowitz G
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6397S-403S. PubMed ID: 15448038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
    Rosen LS; Gordon DH; Dugan W; Major P; Eisenberg PD; Provencher L; Kaminski M; Simeone J; Seaman J; Chen BL; Coleman RE
    Cancer; 2004 Jan; 100(1):36-43. PubMed ID: 14692022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.
    Rosen LS
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):28-32. PubMed ID: 12584692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates: clinical experience.
    Coleman RE
    Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
    Saad F; Chen YM; Gleason DM; Chin J
    Clin Genitourin Cancer; 2007 Sep; 5(6):390-6. PubMed ID: 17956712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
    Saad F; Lipton A
    BJU Int; 2005 Nov; 96(7):964-9. PubMed ID: 16225510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
    Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
    J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for zoledronic acid treatment of patients with bone metastases.
    Berenson JR
    Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.